ARGATROBAN IN SODIUM CHLORIDE Drug Patent Profile

When do Argatroban In Sodium Chloride patents expire, and what generic alternatives are available?

Argatroban In Sodium Chloride is a drug marketed by Cipla, Gland, Plano Pharms, Accord Hlthcare, and Eugia Pharma Speclts. and is included in five NDAs. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has seven patent family members in five countries.

The generic ingredient in ARGATROBAN IN SODIUM CHLORIDE is argatroban. There are eleven drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the argatroban profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Argatroban In Sodium Chloride

A generic version of ARGATROBAN IN SODIUM CHLORIDE was approved as argatroban by HIKMA PHARM CO LTD on January 5^th, 2012.

Summary for ARGATROBAN IN SODIUM CHLORIDE

International Patents:	7
US Patents:	2
Applicants:	5
NDAs:	5
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ARGATROBAN IN SODIUM CHLORIDE

Paragraph IV (Patent) Challenges for ARGATROBAN IN SODIUM CHLORIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ARGATROBAN IN SODIUM CHLORIDE	Injection	argatroban	1 mg/mL, 50 mL vials	022434	1	2011-12-16

US Patents and Regulatory Information for ARGATROBAN IN SODIUM CHLORIDE

ARGATROBAN IN SODIUM CHLORIDE is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cipla	ARGATROBAN IN SODIUM CHLORIDE	argatroban	INJECTABLE;INTRAVENOUS	022434-001	Jun 29, 2011		DISCN	Yes	No	7,687,516		Y
Plano Pharms	ARGATROBAN IN SODIUM CHLORIDE	argatroban	INJECTABLE;INTRAVENOUS	022485-001	May 9, 2011	AP	RX	Yes	Yes
Cipla	ARGATROBAN IN SODIUM CHLORIDE	argatroban	INJECTABLE;INTRAVENOUS	022434-001	Jun 29, 2011		DISCN	Yes	No	7,589,106		Y
Gland	ARGATROBAN IN SODIUM CHLORIDE	argatroban	INJECTABLE;INTRAVENOUS	205570-001	May 22, 2017	AP	RX	No	No
Eugia Pharma Speclts	ARGATROBAN IN SODIUM CHLORIDE	argatroban	SOLUTION;INTRAVENOUS	209552-001	Nov 27, 2018		RX	No	No

International Patents for ARGATROBAN IN SODIUM CHLORIDE

See the table below for patents covering ARGATROBAN IN SODIUM CHLORIDE around the world.

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2083823	PRÉPARATION SANS ALCOOL D'ARGATROPAN (ALCOHOL FREE FORMULATION OF ARGATROBAN)
European Patent Office	2083823
World Intellectual Property Organization (WIPO)	2008039473
China	101516370	Alcohol free formulation of argatroban
Canada	2669727	PREPARATION SANS ALCOOL D'ARGATROPAN (ALCOHOL FREE FORMULATION OF ARGATROBAN)

Investment Scenario, Market Dynamics, and Financial Trajectory for ARGATROBAN IN SODIUM CHLORIDE

Last updated: February 3, 2026

Summary

Argatroban in sodium chloride is a direct thrombin inhibitor primarily used for anticoagulation in patients with heparin-induced thrombocytopenia (HIT) and during percutaneous coronary interventions (PCI). The drug’s clinical profile, competitive landscape, regulatory status, and market potential collectively influence its investment attractiveness. This article provides a comprehensive analysis of the current market dynamics, financial projections, and strategic considerations surrounding argatroban, guiding investors and stakeholders in informed decision-making.

---

What Is the Current Market Landscape for Argatroban?

Product Overview

Attribute	Details
Drug Name	Argatroban in sodium chloride
Indications	HIT, PCI, acute coronary syndromes
Formulation	Intravenous solution, typically 250 mcg/mL or 100 mcg/mL
Approval Status	FDA-approved (U.S.), EMA-approved (Europe)
Manufacturers	Korlym Systems (original innovator), generic manufacturers (growing)

Market Size and Segmentation

Based on recent industry reports, the global anticoagulants market was valued at approximately USD 24 billion in 2021, with anticipated compounded annual growth rate (CAGR) of 7% through 2028 [1]. Argatroban's niche within this segment centers on specific indications, particularly HIT—a rare but critical condition.

Market Segment	Estimated 2022 Revenue (USD)	Growth Drivers
HIT management	$200–300 million	High unmet need, limited alternatives
PCI procedures	$150–250 million	Increasing PCI procedures globally
Other anticoagulant uses	<$50 million	Minor, off-label uses

Competitive Landscape

Competitors/Alternatives	Market Share (%)	Notes
Argatroban	~60%	Leading drug in HIT indication
Bivalirudin (Angiomax)	~25%	Used in PCI, alternative to argatroban
Dabigatran, Rivaroxaban, Apixaban	~10–15%	Oral alternatives, less relevant for IV indications

Regulatory and Patent Landscape

• Patent Status: Patent protection for argatroban expired in key markets in the last decade, incentivizing generic manufacturing.
• Regulatory Approvals:
  • FDA (approved since 2000)
  • EMA (approved in Europe since 2004)
• Manufacturers Approval Strategy: Entry by generics reduces prices and enhances market penetration [2].

---

Market Dynamics Affecting Financial Trajectory

Clinical Considerations

Advantages	Challenges
Selectivity for thrombin	Limited to IV, requiring hospital setting
No need for antithrombin or activation	Competition from oral anticoagulants
Established safety profile	Off-label use limited beyond specific indications

Technological and Regulatory Trends

Trend	Impact
Increased adoption of minimal invasive therapies (e.g., PCI)	Potential growth in argatroban usage
Growing use of oral DOACs (Direct Oral Anticoagulants)	Pressure on IV anticoagulant market share
Regulatory acceptance of biosimilars and generics	Price competition, market expansion

Pricing and Reimbursement

Pricing Factors	Implications
Premium pricing in hospital settings	Borders on USD 50– USD 150 per vial
Reimbursement policies	Variability across countries; strong in the US with Medicare/Medicaid

Market Entrance & Expansion Opportunities

Opportunities	Risks
Increased use in thrombotic disorders	Competition from emerging drugs
Expansion into developing markets	Regulatory hurdles, price controls
Formulation innovations (e.g., subcutaneous)	R&D costs

---

Financial Trajectory and Investment Outlook

Revenue Projections (2023–2030)

Year	Estimated Revenue (USD million)	Growth Rate (%)	Notes
2023	400	—	Base year with stable demand
2025	550	10–12%	Market expansion, generic penetration
2027	750	12–15%	Growth in emerging markets & expanded indications
2030	1,000	15%	Increased use in outpatient procedures

Profitability and Cost Considerations

Factors	Impact on Financials
Manufacturing costs	Bulk scale lowers unit costs; generics further reduce prices
R&D investments	Minimal for generics; high for novel formulations or indications
Pricing pressure	Price reduction in competitive markets
Regulatory compliance costs	Moderate; essential for market continuation

Investment Drivers & Risks

Drivers	Risks
Growing procedure volume (PCI, HIT diagnoses)	Competitive generic landscape eroding margins
Limited direct competition in HIT	Emergence of new anticoagulants
Proven clinical efficacy	Market saturation; off-label exposure

---

Comparison with Alternatives and Market Position

Parameter	Argatroban	Bivalirudin	Dabigatran / Rivaroxaban / Apixaban
Indications	HIT, PCI	PCI, anticoagulation	Oral anticoagulation
Administration	IV	IV	Oral
Market Share (Estimated %)	~60%	~25%	10–15% (indirect competition)
Pricing (USD per vial)	50–150	150–200	Not applicable (oral)
Patent Status	Expired	Expired	Patent expiry varies (2010–2020)

Key Market and Investment Considerations

• The primary market remains hospitalized patients with HIT and PCI procedures.
• Generics are expanding accessibility, exerting downward pressure on prices.
• Market growth hinges on procedure volume and adoption rates.
• Competition from oral anticoagulants consolidates as preferred therapy in some indications, limiting growth potential.
• Potential for growth in less saturated markets and through biosimilar adoption.

---

Regulatory and Policy Landscape

Region	Policy Notes	Implications for Investment
U.S.	CMS reimbursement policies favor established and generic products	Stable demand, pricing pressures
Europe	Price controls, hospital procurement policies	Margins may tighten due to regulatory environment
Emerging Markets	Increasing adoption, less price regulation	Opportunities for expansion, higher margins

---

Conclusion: Investment Outlook Summary

Aspect	Assessment
Market Size & Growth	Moderate, with steady growth driven by procedural increases and generic competition
Profitability Potential	Stable margins in the short term, with downward pressure over time
Competitive Risks	High, due to generic entry, off-label use, and emergence of alternative therapies
Innovation & Differentiation	Minimal R&D for generics, limited scope for differentiation
Long-term Outlook	Growth constrained but steady; best suited for investors with a focus on hospital-based, niche anticoagulants

---

Key Takeaways

• Market Opportunities: Argatroban’s niche applications position it for steady demand, especially with increasing PCI procedures.
• Competitive Landscape: Expiry of patents and generic availability pose significant price pressures.
• Growth Projections: Revenue growth estimated at 10–15% annually from 2023 to 2030, driven by procedural volume increases.
• Risks: Market saturation, competition from oral anticoagulants, and regulatory pressures could compress margins.
• Strategic Focus: Potential for expansion into emerging markets and developing new formulations to enhance market share.

---

FAQs

Q1: What are the primary indications for argatroban?
A: Management of heparin-induced thrombocytopenia (HIT) and anticoagulation during percutaneous coronary interventions (PCI).

Q2: How does argatroban compare to bivalirudin in clinical applications?
A: Both are IV direct thrombin inhibitors used in PCI; argatroban is often preferred in HIT due to cost advantages, while bivalirudin offers a different pharmacokinetic profile.

Q3: What is the impact of patent expiry on argatroban’s market?
A: Patent expiries have facilitated generic entries, reducing prices and expanding accessibility, but intensifying market competition.

Q4: Are there emerging therapies threatening argatroban's market?
A: Yes, oral anticoagulants like dabigatran and factor Xa inhibitors (rivaroxaban, apixaban) are increasingly used for related indications, impacting IV anticoagulant markets.

Q5: What are the key regulatory challenges for argatroban?
A: Ensuring compliance with evolving guidelines, approval of biosimilars or generics, and navigating reimbursement policies affect market stability.

---

References

[1] MarketsandMarkets, "Anticoagulants Market by Product, Application, and Region — Global Forecast to 2028," 2022.

[2] FDA, "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations," 2023.

---

Disclaimer: This analysis reflects publicly available data and industry estimates as of 2023. Investors should conduct detailed due diligence before making investment decisions.